Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000393073

Medchemexpress LLC KVS0001 | 3056394-59-0 | 99.1% | 579.07 | 50 MG
SDP

Catalog No. 5000393073
Encompass_Preferred

KVS0001 is a selective SMG1 inhibitor that elevates the expression of transcripts and proteins resulting from truncating mutations. It increases the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. This compound exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases.

  • Inhibits SMG1 protein more selectively than other kinases.
  • Subverts nonsense-mediated decay (NMD)-mediated downregulation of mutant transcripts and proteins.
  • Increases interferon-gamma (IFN-γ) release and killing of target cancer cells.
  • Significantly increases RNA in genes with truncating mutations.
  • Slows tumor growth in C57BL/6N and BALB/c mouse models.
  • Increases transcript levels in genes with truncating mutations in xenograft tumors.

Catalog No. 50-003-93073 Supplier Medchemexpress LLC Supplier No. HY16111150MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

KVS0001 is a selective SMG1 inhibitor that elevates the expression of transcripts and proteins resulting from truncating mutations. It increases the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. This compound exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases.

  • Inhibits SMG1 protein more selectively than other kinases.
  • Subverts nonsense-mediated decay (NMD)-mediated downregulation of mutant transcripts and proteins.
  • Increases interferon-gamma (IFN-γ) release and killing of target cancer cells.
  • Significantly increases RNA in genes with truncating mutations.
  • Slows tumor growth in C57BL/6N and BALB/c mouse models.
  • Increases transcript levels in genes with truncating mutations in xenograft tumors.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.